ONTX) decreased 1.89% in after-market trading after the company reported Q2 results.
Earnings per share rose 93.33% over the past year to ($0.04), which missed the estimate of ($0.03).
Revenue of $56,000 declined by 97.23% year over year, which missed the estimate of $170,000.
Earnings guidance hasn’t been issued by the company for now.
Onconova Therapeutics hasn’t issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 12, 2020
View more earnings on ONTX” data-reactid=”25″>View more earnings on ONTX
Time: 04:30 PM
https://edge.media-server.com/mmc/p/2eia58p4” data-reactid=”27″>ET Webcast URL: https://edge.media-server.com/mmc/p/2eia58p4
Recent Stock Performance
52-week high: $2.84
52-week low: $0.10
Price action over last quarter: Up 202.02%
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways.
View Article Origin Here